A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany
NCT07653126 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117
Last updated 2026-06-17
Summary
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-03
- Primary Completion
- 2023-09-29
- Completion
- 2023-09-29
Countries
- Germany
Study Locations
More Related Trials
-
Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
NCT06256705 ·Status: RECRUITING ·Phase: NA
-
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
NCT02231762 ·Status: COMPLETED ·Phase: PHASE2
-
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
NCT02736500 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients
NCT03422029 ·Status: UNKNOWN ·Phase: PHASE2
-
Biomarker Identification of Radionuclide Therapy-induced Radiation Responses
NCT05513469 ·Status: UNKNOWN ·Phase: NA
-
Randomized Phase III of PRRT Versus Interferon
NCT01860742 ·Status: WITHDRAWN ·Phase: PHASE3
-
Best Therapy for Patients With Neuroendocrine Tumors
NCT00815620 ·Status: COMPLETED
-
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)
NCT04790708 ·Status: UNKNOWN ·Phase: NA
-
A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
NCT02788578 ·Status: TERMINATED
-
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
NCT06045260 ·Status: RECRUITING ·Phase: PHASE2
-
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
NCT05387603 ·Status: RECRUITING ·Phase: PHASE3
-
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
NCT07538791 ·Status: NOT_YET_RECRUITING
-
Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
NCT04917484 ·Status: RECRUITING ·Phase: PHASE2
-
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
NCT02736448 ·Status: TERMINATED ·Phase: PHASE2
-
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
NCT01873248 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate
NCT02125474 ·Status: COMPLETED ·Phase: NA
-
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
NCT03724409 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
NCT03273712 ·Status: COMPLETED ·Phase: PHASE2
-
Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
NCT02358356 ·Status: COMPLETED ·Phase: PHASE2
-
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
NCT03112694 ·Status: COMPLETED
-
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
NCT07012330 ·Status: TERMINATED ·Phase: PHASE2
-
[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
NCT03724253 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
NCT07661641 ·Status: RECRUITING ·Phase: PHASE1
-
HRQoL During PRRT in Patients With NETs
NCT05427032 ·Status: COMPLETED
-
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
NCT03197012 ·Status: COMPLETED ·Phase: EARLY_PHASE1